Abstract:Rett syndrome1 (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females, with an incidence of 1 in 10,000–15,000 (ref. 2). Patients with classic RTT appear to develop normally until 6–18 months of age, then gradually lose speech and purposeful hand use, and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements3. After initial regression, the condition stabilizes and patients usually survive into adulthood. As RTT occurs almost exclusively in females, it has been proposed that RTT is caused by an X-linked dominant mutation with lethality in hemizygous males3,4,5,6,7,8. Previous exclusion mapping studies using RTT families mapped the locus to Xq28 (refs 6,9,10,11). Using a systematic gene screening approach, we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT. MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (refs 12,13). In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD). In two affected half-sisters of a RTT family, we found segregation of an additional missense mutation not detected in their obligate carrier mother. This suggests that the mother is a germline mosaic for this mutation. Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Rett Syndrome-Causing Mutations Compromise MeCP2-mediated Liquid–liquid Phase Separation of Chromatin

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Activity-dependent aberrations in gene expression and alternative splicing in a mouse model of Rett syndrome.

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

X Chromosome Inactivation in Rett Syndrome and Its Correlations with MECP2 Mutations and Phenotype.

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

Loss of MeCP2 in Aminergic Neurons Causes Cell-Autonomous Defects in Neurotransmitter Synthesis and Specific Behavioral Abnormalities

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

The molecular pathology of rett syndrome

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Molecular Mechanisms of Rett Syndrome: Emphasizing the Roles of Monoamine, Immunity, and Mitochondrial Dysfunction

Genome-Wide Analysis Reveals Methyl-Cpg-Binding Protein 2-Dependent Regulation Of Micrornas In A Mouse Model Of Rett Syndrome

Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes

Loss of MeCP2 in Cholinergic Neurons Causes Part of RTT-like Phenotypes Via Α7 Receptor in Hippocampus